GALT CMO exercises options, sells 7,557 shares
GALECTIN THERAPEUTICS INC Chief Medical Officer Jamil Khurram exercised stock options and sold the resulting shares in a planned transaction.
Rhea-AI Filing Summary
GALECTIN THERAPEUTICS INC Chief Medical Officer Jamil Khurram exercised stock options and sold the resulting shares in a planned transaction. He exercised options to acquire 7,557 shares of common stock at $1.23 per share, then sold 7,557 shares at a weighted average price of $3.14 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 2, 2026, indicating it was scheduled in advance. Following these transactions, he reported no directly held common shares and 32,500 stock options outstanding, with remaining options vesting in tranches of 16,250 on specified future dates.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 7,557 shares ($14K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Jamil Khurram
Role
Chief Medical Officer
Sold
7,557 shs ($24K)
Approx. gross sale proceeds
$24K
Approx. exercise cost
$9K
Approx. pre-tax spread
$14K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) | 7,557 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,557 | $1.23 | $9K |
| Sale | Common Stock | 7,557 | $3.14 | $24K |
Holdings After Transaction:
Stock option (right to buy) — 32,500 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (3)
- F1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026
- F2. The shares were sold in multiple transactions at prices ranging from $3.10 to $3.17. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3. The options vested as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026.
Key Figures
Shares sold: 7,557 shares
Sale price: $3.14 per share
Options exercised: 7,557 options
+4 more
7 metrics
Shares sold
7,557 shares
Common stock sold on June 23, 2026
Sale price
$3.14 per share
Weighted average sale price for 7,557 shares
Options exercised
7,557 options
Stock options converted into common stock
Option exercise price
$1.23 per share
Conversion or exercise price for options
Options remaining
32,500 options
Stock options outstanding after the exercise
Option expiration
January 23, 2035
Expiration date of the option grant
Vesting tranches
16,250 options each
Vesting on June 30, 2025; Dec 31, 2025; June 30, 2026; Dec 31, 2026
Key Terms
Rule 10b5-1 plan, weighted average sale price, Stock option (right to buy), exercise or conversion of derivative security, +1 more
5 terms
Rule 10b5-1 plan regulatory
"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average sale price financial
"The shares were sold in multiple transactions at prices ranging from $3.10 to $3.17. This amount represents the weighted average sale price"
Stock option (right to buy) financial
"security_title: "Stock option (right to buy)""
exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
expiration date financial
"expiration_date: "2035-01-23T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did GALT Chief Medical Officer Jamil Khurram do in this Form 4?
Jamil Khurram exercised stock options for 7,557 Galectin Therapeutics common shares at $1.23 each and sold 7,557 shares at a weighted average price of $3.14 per share. The transactions are reported as direct holdings activity for the Chief Medical Officer.
Was the GALT insider sale by Jamil Khurram pre-planned under a Rule 10b5-1 plan?
Yes. The filing states the sale was made under a Rule 10b5-1 trading plan adopted on February 2, 2026. Such plans schedule trades in advance, making the timing more routine and less about short-term views on Galectin Therapeutics stock.
What stock options did Jamil Khurram exercise in this GALT Form 4?
He exercised stock options covering 7,557 underlying Galectin Therapeutics common shares at a conversion or exercise price of $1.23 per share. These options are part of a grant expiring on January 23, 2035, with vesting occurring in scheduled tranches.
What are Jamil Khurram’s remaining GALT option holdings after these transactions?
After exercising 7,557 options, he reported 32,500 stock options remaining. Footnotes explain the options vest in four tranches of 16,250 each on June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026, supporting ongoing equity exposure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
